Videos

July 01, 2022

David Barrington, MD, discusses the key takeaways regarding the factors associated with variation of adjuvant treatments for patients with stage 1B, grade 3 endometrial cancer.

June 30, 2022

Andreas Saltos, MD, discusses the key takeaways of the phase 1/1b clinical trial exploring the use of binimetinib plus erlotinib in patients with non–small cell lung cancer harboring either KRAS or EGFR mutations.

June 30, 2022

Robert Zeiser, MD, reviews the pathophysiology of graft versus host disease and explains its relationship to the desired graft versus leukemia effect.

June 30, 2022

Moshe Orenstein, MD, gives a brief overview of an exciting upcoming Targeted Oncology Virtual Tumor Board series titled "Advances in Frontline Treatment for Advanced Renal Cell Carcinoma."

June 30, 2022

Eytan Stein, MD, provides a brief overview of acute myeloid leukemia.

June 30, 2022

In this companion article, Dr. Estelamari Rodriguez reflects on the role of reactive and proactive treatment approaches for the management of chemotherapy-induced myelosuppression in small cell lung cancer.

June 30, 2022

Yelena Ginzburg, MD, discusses a long-term goal of the use of rusfertide (PTG-300) in patients with chronic polycythemia vera.

June 29, 2022

Joshua K. Sabari, MD, discusses the significance of EGFR exon 20 insertion mutations in patients with non–small cell lung cancer.

June 29, 2022

A broad review of CNS-related clinical trial data in the setting of HER2+ breast cancer and concurrent brain metastases.

June 29, 2022

Grzegorz S. Nowakowski, MD, presents the case of a woman with relapsed DLBLC and provides his initial impressions.